BMC Cancer 2020 May 5
Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
Related Questions
If a patient presents with de novo oligometastatic (i.e., meeting STAMPEDE low met burden criteria) prostate cancer with no prior history of primary t...
New answer by Radiation Oncologist at University of Texas at Tyler (December 16, 2024)
The PEACE 1 trial on de novo metastatic, castration-sensitive prostate cancer is now published for radiotherapy and is noteworthy for several beneficial and clinically relevan...